Skip to content

Study · Non-randomized trial · n = 13 · 1994

21 results

Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women.

Holloway L, Butterfield G, Hintz RL, Gesundheit N, Marcus R

The Journal of clinical endocrinology and metabolism1 Aug 1994Cited by 152 (Europe PMC)

PMID7519191 (opens in a new tab)DOI10.1210/jcem.79.2.7519191 (opens in a new tab)PepBankPUB-07519191
Publisher pagePubMedAsk about this study
Jump to 21 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study21

21 results from studies that gave the peptide. 21 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy elderly women, rhGH increased IGFBP-3 in all subjects.

    In plain wordsIn healthy elderly women, IGFBP-3 increased during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseIGFBP-3
    Study

    n = 13

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Initially 0.043 mg/kg daily, with 50% reductions for side-effects; the last 7 subjects began at the reduced dose · injection · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    rhGH increased IGF-I and IGF-I-binding protein-3 (IGFBP-3) in all subjects [6 month IGF-I in plus estrogen women, 230 +/- 25.4 micrograms/L; in those not receiving estrogen (minus estrogen), 308 +/- 21.3].
    5 context sentences
    Summary · context
    We conducted a controlled trial of recombinant human GH (rhGH) in 27 healthy elderly women (66.7 +/- 3.0 yr), of whom 8 took a stable dose of replacement estrogen throughout the study (plus estrogen group).
    Summary · context
    Hormone or placebo was given as a single daily injection.
    Summary · context
    A total of 19 women were assigned to receive rhGH at an initial daily dose of 0.043 mg/kg BW.
    Summary · context
    A total of 13 women assigned to rhGH and 14 women assigned to placebo completed 6 months of drug treatment.
    Summary · context
    In the rhGH group, 6 women took estrogen; thus, the effects of rhGH were assessed separately by estrogen status.
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy elderly women, fat mass decreased by 11% after 6 months of rhGH treatment (P < 0.005).

    In plain wordsIn healthy elderly women, fat mass decreased by 11% during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseFat mass
    Study

    n = 13

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Initially 0.043 mg/kg daily, with 50% reductions for side-effects; the last 7 subjects began at the reduced dose · injection · 6 monthsAs given in this study (human).

    Measurements

    Fat mass decrease (skinfold thickness)
    11%
    after 6 months of rhGH

    Source sentences

    Summary
    Skinfold thickness measurements showed an 11% decrease in fat mass (P < 0.005) and a 9% decrease in percent fat after 6 months of rhGH treatment.
    5 context sentences
    Summary · context
    We conducted a controlled trial of recombinant human GH (rhGH) in 27 healthy elderly women (66.7 +/- 3.0 yr), of whom 8 took a stable dose of replacement estrogen throughout the study (plus estrogen group).
    Summary · context
    Hormone or placebo was given as a single daily injection.
    Summary · context
    A total of 19 women were assigned to receive rhGH at an initial daily dose of 0.043 mg/kg BW.
    Summary · context
    A total of 13 women assigned to rhGH and 14 women assigned to placebo completed 6 months of drug treatment.
    Summary · context
    In the rhGH group, 6 women took estrogen; thus, the effects of rhGH were assessed separately by estrogen status.
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy elderly women, percent fat decreased by 9% after 6 months of rhGH treatment.

    In plain wordsIn healthy elderly women, percent fat decreased by 9% during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreasePercent fat
    Study

    n = 13

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Initially 0.043 mg/kg daily, with 50% reductions for side-effects; the last 7 subjects began at the reduced dose · injection · 6 monthsAs given in this study (human).

    Measurements

    Percent fat decrease (skinfold thickness)
    9%
    after 6 months of rhGH

    Source sentences

    Summary
    Skinfold thickness measurements showed an 11% decrease in fat mass (P < 0.005) and a 9% decrease in percent fat after 6 months of rhGH treatment.
    5 context sentences
    Summary · context
    We conducted a controlled trial of recombinant human GH (rhGH) in 27 healthy elderly women (66.7 +/- 3.0 yr), of whom 8 took a stable dose of replacement estrogen throughout the study (plus estrogen group).
    Summary · context
    Hormone or placebo was given as a single daily injection.
    Summary · context
    A total of 19 women were assigned to receive rhGH at an initial daily dose of 0.043 mg/kg BW.
    Summary · context
    A total of 13 women assigned to rhGH and 14 women assigned to placebo completed 6 months of drug treatment.
    Summary · context
    In the rhGH group, 6 women took estrogen; thus, the effects of rhGH were assessed separately by estrogen status.
  4. 04HumanNon-randomized trialEfficacy outcome

    In healthy elderly women, nitrogen balance did not change significantly at 6 months in either rhGH or placebo groups.

    In plain wordsIn healthy elderly women, nitrogen balance did not change significantly during rhGH or placebo treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeNitrogen balance
    Study

    n = 13

    Comparator
    Placebo
    Outcome group
    Protein and amino acid metabolism · Metabolic and weight
    Studied dose
    Initially 0.043 mg/kg daily, with 50% reductions for side-effects; the last 7 subjects began at the reduced dose · injection · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    No significant difference in nitrogen balance was seen in either group at 6 months, but rhGH increased creatinine clearance by 9.2% (P < 0.05). rhGH dramatically increased markers of bone turnover, with more pronounced effects in minus estrogen women.
    5 context sentences
    Summary · context
    We conducted a controlled trial of recombinant human GH (rhGH) in 27 healthy elderly women (66.7 +/- 3.0 yr), of whom 8 took a stable dose of replacement estrogen throughout the study (plus estrogen group).
    Summary · context
    Hormone or placebo was given as a single daily injection.
    Summary · context
    A total of 19 women were assigned to receive rhGH at an initial daily dose of 0.043 mg/kg BW.
    Summary · context
    A total of 13 women assigned to rhGH and 14 women assigned to placebo completed 6 months of drug treatment.
    Summary · context
    In the rhGH group, 6 women took estrogen; thus, the effects of rhGH were assessed separately by estrogen status.
  5. 05HumanNon-randomized trialEfficacy outcome

    In healthy elderly women, rhGH increased creatinine clearance by 9.2% (P < 0.05).

    In plain wordsIn healthy elderly women, creatinine clearance increased by 9.2% during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseCreatinine clearance
    Study

    n = 13

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Initially 0.043 mg/kg daily, with 50% reductions for side-effects; the last 7 subjects began at the reduced dose · injection · 6 monthsAs given in this study (human).

    Measurements

    Creatinine clearance increase
    9.2%
    after 6 months of rhGH

    Source sentences

    Summary
    No significant difference in nitrogen balance was seen in either group at 6 months, but rhGH increased creatinine clearance by 9.2% (P < 0.05). rhGH dramatically increased markers of bone turnover, with more pronounced effects in minus estrogen women.
    5 context sentences
    Summary · context
    We conducted a controlled trial of recombinant human GH (rhGH) in 27 healthy elderly women (66.7 +/- 3.0 yr), of whom 8 took a stable dose of replacement estrogen throughout the study (plus estrogen group).
    Summary · context
    Hormone or placebo was given as a single daily injection.
    Summary · context
    A total of 19 women were assigned to receive rhGH at an initial daily dose of 0.043 mg/kg BW.
    Summary · context
    A total of 13 women assigned to rhGH and 14 women assigned to placebo completed 6 months of drug treatment.
    Summary · context
    In the rhGH group, 6 women took estrogen; thus, the effects of rhGH were assessed separately by estrogen status.
  6. 06HumanNon-randomized trialEfficacy outcome

    In healthy elderly women, circulating type I procollagen extension peptide did not change in either rhGH or placebo groups.

    In plain wordsIn healthy elderly women, type I procollagen extension peptide did not change during rhGH or placebo treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeType I procollagen extension peptide
    Study

    n = 13

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Initially 0.043 mg/kg daily, with 50% reductions for side-effects; the last 7 subjects began at the reduced dose · injection · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    No changes were observed in circulating type I procollagen extension peptide in either group, and no change in any turnover marker was seen in the placebo group.
    5 context sentences
    Summary · context
    We conducted a controlled trial of recombinant human GH (rhGH) in 27 healthy elderly women (66.7 +/- 3.0 yr), of whom 8 took a stable dose of replacement estrogen throughout the study (plus estrogen group).
    Summary · context
    Hormone or placebo was given as a single daily injection.
    Summary · context
    A total of 19 women were assigned to receive rhGH at an initial daily dose of 0.043 mg/kg BW.
    Summary · context
    A total of 13 women assigned to rhGH and 14 women assigned to placebo completed 6 months of drug treatment.
    Summary · context
    In the rhGH group, 6 women took estrogen; thus, the effects of rhGH were assessed separately by estrogen status.
  7. 07HumanNon-randomized trialEfficacy outcome

    In healthy elderly women, rhGH did not alter blood pressure.

    In plain wordsIn healthy elderly women, blood pressure did not change during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeBlood pressure
    Study

    n = 13

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Initially 0.043 mg/kg daily, with 50% reductions for side-effects; the last 7 subjects began at the reduced dose · injection · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    rhGH did not alter blood pressure or circulating L-T4 levels, but a transient increase in serum T3 was observed in the minus estrogen group at 3 months.
    5 context sentences
    Summary · context
    We conducted a controlled trial of recombinant human GH (rhGH) in 27 healthy elderly women (66.7 +/- 3.0 yr), of whom 8 took a stable dose of replacement estrogen throughout the study (plus estrogen group).
    Summary · context
    Hormone or placebo was given as a single daily injection.
    Summary · context
    A total of 19 women were assigned to receive rhGH at an initial daily dose of 0.043 mg/kg BW.
    Summary · context
    A total of 13 women assigned to rhGH and 14 women assigned to placebo completed 6 months of drug treatment.
    Summary · context
    In the rhGH group, 6 women took estrogen; thus, the effects of rhGH were assessed separately by estrogen status.
  8. 08HumanNon-randomized trialEfficacy outcome

    In healthy elderly women, rhGH did not alter circulating L-T4.

    In plain wordsIn healthy elderly women, circulating L-T4 did not change during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeCirculating L-T4
    Study

    n = 13

    Outcome group
    Thyroid function · Endocrine and hormones
    Studied dose
    Initially 0.043 mg/kg daily, with 50% reductions for side-effects; the last 7 subjects began at the reduced dose · injection · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    rhGH did not alter blood pressure or circulating L-T4 levels, but a transient increase in serum T3 was observed in the minus estrogen group at 3 months.
    5 context sentences
    Summary · context
    We conducted a controlled trial of recombinant human GH (rhGH) in 27 healthy elderly women (66.7 +/- 3.0 yr), of whom 8 took a stable dose of replacement estrogen throughout the study (plus estrogen group).
    Summary · context
    Hormone or placebo was given as a single daily injection.
    Summary · context
    A total of 19 women were assigned to receive rhGH at an initial daily dose of 0.043 mg/kg BW.
    Summary · context
    A total of 13 women assigned to rhGH and 14 women assigned to placebo completed 6 months of drug treatment.
    Summary · context
    In the rhGH group, 6 women took estrogen; thus, the effects of rhGH were assessed separately by estrogen status.
  9. 09HumanNon-randomized trialEfficacy outcome

    In healthy elderly women, other circulating lipoproteins showed no significant changes during rhGH treatment.

    In plain wordsIn healthy elderly women, other circulating lipoproteins did not change significantly during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeOther circulating lipoproteins
    Study

    n = 13

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Initially 0.043 mg/kg daily, with 50% reductions for side-effects; the last 7 subjects began at the reduced dose · injection · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    rhGH decreased low density lipoprotein cholesterol in the minus estrogen group, but otherwise no significant changes in circulating lipoproteins or fibrinogen were observed.
    5 context sentences
    Summary · context
    We conducted a controlled trial of recombinant human GH (rhGH) in 27 healthy elderly women (66.7 +/- 3.0 yr), of whom 8 took a stable dose of replacement estrogen throughout the study (plus estrogen group).
    Summary · context
    Hormone or placebo was given as a single daily injection.
    Summary · context
    A total of 19 women were assigned to receive rhGH at an initial daily dose of 0.043 mg/kg BW.
    Summary · context
    A total of 13 women assigned to rhGH and 14 women assigned to placebo completed 6 months of drug treatment.
    Summary · context
    In the rhGH group, 6 women took estrogen; thus, the effects of rhGH were assessed separately by estrogen status.
  10. 10HumanNon-randomized trialEfficacy outcome

    In healthy elderly women, fibrinogen showed no significant change during rhGH treatment.

    In plain wordsIn healthy elderly women, fibrinogen did not change significantly during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeFibrinogen
    Study

    n = 13

    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    Initially 0.043 mg/kg daily, with 50% reductions for side-effects; the last 7 subjects began at the reduced dose · injection · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    rhGH decreased low density lipoprotein cholesterol in the minus estrogen group, but otherwise no significant changes in circulating lipoproteins or fibrinogen were observed.
    5 context sentences
    Summary · context
    We conducted a controlled trial of recombinant human GH (rhGH) in 27 healthy elderly women (66.7 +/- 3.0 yr), of whom 8 took a stable dose of replacement estrogen throughout the study (plus estrogen group).
    Summary · context
    Hormone or placebo was given as a single daily injection.
    Summary · context
    A total of 19 women were assigned to receive rhGH at an initial daily dose of 0.043 mg/kg BW.
    Summary · context
    A total of 13 women assigned to rhGH and 14 women assigned to placebo completed 6 months of drug treatment.
    Summary · context
    In the rhGH group, 6 women took estrogen; thus, the effects of rhGH were assessed separately by estrogen status.
  11. 11HumanNon-randomized trialEfficacy outcome

    In healthy elderly women receiving estrogen, rhGH increased IGF-I, reaching 230 +/- 25.4 micrograms/L at 6 months.

    In plain wordsIn healthy elderly women receiving estrogen, IGF-I increased during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseIGF-I with estrogen
    Study

    n = 6

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Initially 0.043 mg/kg daily, with 50% reductions for side-effects; the last 7 subjects began at the reduced dose · injection · 6 monthsAs given in this study (human).

    Measurements

    IGF-I at 6 months
    230 micrograms/L
    rhGH, plus estrogen women
    IGF-I at 6 months, plus-minus spread (SD or SEM not stated)
    25.4 micrograms/L
    rhGH, plus estrogen women

    Source sentences

    Summary
    rhGH increased IGF-I and IGF-I-binding protein-3 (IGFBP-3) in all subjects [6 month IGF-I in plus estrogen women, 230 +/- 25.4 micrograms/L; in those not receiving estrogen (minus estrogen), 308 +/- 21.3].
    5 context sentences
    Summary · context
    We conducted a controlled trial of recombinant human GH (rhGH) in 27 healthy elderly women (66.7 +/- 3.0 yr), of whom 8 took a stable dose of replacement estrogen throughout the study (plus estrogen group).
    Summary · context
    Hormone or placebo was given as a single daily injection.
    Summary · context
    A total of 19 women were assigned to receive rhGH at an initial daily dose of 0.043 mg/kg BW.
    Summary · context
    A total of 13 women assigned to rhGH and 14 women assigned to placebo completed 6 months of drug treatment.
    Summary · context
    In the rhGH group, 6 women took estrogen; thus, the effects of rhGH were assessed separately by estrogen status.
  12. 12HumanNon-randomized trialEfficacy outcome

    In healthy elderly women receiving estrogen, hydroxyproline excretion increased by 20% during rhGH treatment.

    In plain wordsIn healthy elderly women receiving estrogen, hydroxyproline excretion increased by 20% during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHydroxyproline excretion with estrogen
    Study

    n = 6

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Initially 0.043 mg/kg daily, with 50% reductions for side-effects; the last 7 subjects began at the reduced dose · injection · 6 monthsAs given in this study (human).

    Measurements

    Hydroxyproline excretion increase
    20%
    rhGH, plus estrogen subgroup

    Source sentences

    Summary
    Hydroxyproline excretion increased by 20% and 80%, and pyridinoline excretion increased by 44% and 75% in plus and minus estrogen subgroups, respectively.
    5 context sentences
    Summary · context
    We conducted a controlled trial of recombinant human GH (rhGH) in 27 healthy elderly women (66.7 +/- 3.0 yr), of whom 8 took a stable dose of replacement estrogen throughout the study (plus estrogen group).
    Summary · context
    Hormone or placebo was given as a single daily injection.
    Summary · context
    A total of 19 women were assigned to receive rhGH at an initial daily dose of 0.043 mg/kg BW.
    Summary · context
    A total of 13 women assigned to rhGH and 14 women assigned to placebo completed 6 months of drug treatment.
    Summary · context
    In the rhGH group, 6 women took estrogen; thus, the effects of rhGH were assessed separately by estrogen status.
  13. 13HumanNon-randomized trialEfficacy outcome

    In healthy elderly women receiving estrogen, pyridinoline excretion increased by 44% during rhGH treatment.

    In plain wordsIn healthy elderly women receiving estrogen, pyridinoline excretion increased by 44% during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreasePyridinoline excretion with estrogen
    Study

    n = 6

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Initially 0.043 mg/kg daily, with 50% reductions for side-effects; the last 7 subjects began at the reduced dose · injection · 6 monthsAs given in this study (human).

    Measurements

    Pyridinoline excretion increase
    44%
    rhGH, plus estrogen subgroup

    Source sentences

    Summary
    Hydroxyproline excretion increased by 20% and 80%, and pyridinoline excretion increased by 44% and 75% in plus and minus estrogen subgroups, respectively.
    5 context sentences
    Summary · context
    We conducted a controlled trial of recombinant human GH (rhGH) in 27 healthy elderly women (66.7 +/- 3.0 yr), of whom 8 took a stable dose of replacement estrogen throughout the study (plus estrogen group).
    Summary · context
    Hormone or placebo was given as a single daily injection.
    Summary · context
    A total of 19 women were assigned to receive rhGH at an initial daily dose of 0.043 mg/kg BW.
    Summary · context
    A total of 13 women assigned to rhGH and 14 women assigned to placebo completed 6 months of drug treatment.
    Summary · context
    In the rhGH group, 6 women took estrogen; thus, the effects of rhGH were assessed separately by estrogen status.
  14. 14HumanNon-randomized trialEfficacy outcome

    In healthy elderly women receiving estrogen, osteocalcin did not change during rhGH treatment.

    In plain wordsIn healthy elderly women receiving estrogen, osteocalcin did not change during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeOsteocalcin with estrogen
    Study

    n = 6

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Initially 0.043 mg/kg daily, with 50% reductions for side-effects; the last 7 subjects began at the reduced dose · injection · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Osteocalcin concentrations increased by more than 60% in minus estrogen women (P < 0.05), but did not change in the plus estrogen group.
    5 context sentences
    Summary · context
    We conducted a controlled trial of recombinant human GH (rhGH) in 27 healthy elderly women (66.7 +/- 3.0 yr), of whom 8 took a stable dose of replacement estrogen throughout the study (plus estrogen group).
    Summary · context
    Hormone or placebo was given as a single daily injection.
    Summary · context
    A total of 19 women were assigned to receive rhGH at an initial daily dose of 0.043 mg/kg BW.
    Summary · context
    A total of 13 women assigned to rhGH and 14 women assigned to placebo completed 6 months of drug treatment.
    Summary · context
    In the rhGH group, 6 women took estrogen; thus, the effects of rhGH were assessed separately by estrogen status.
  15. 15HumanNon-randomized trialSafety outcome

    In healthy elderly women receiving rhGH, side-effects required 50% dose reductions after several weeks.

    In plain wordsIn healthy elderly women receiving rhGH, side-effects required 50% dose reductions after several weeks.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableDose reduction for side-effects
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Initially 0.043 mg/kg daily, with 50% reductions for side-effects; the last 7 subjects began at the reduced dose · injection · Several weeksAs given in this study (human).

    Measurements

    Dose reduction
    50%
    after several weeks, necessitated by side-effects

    Source sentences

    Summary
    After several weeks, 50% dose reductions were necessitated by side-effects.
    5 context sentences
    Summary · context
    We conducted a controlled trial of recombinant human GH (rhGH) in 27 healthy elderly women (66.7 +/- 3.0 yr), of whom 8 took a stable dose of replacement estrogen throughout the study (plus estrogen group).
    Summary · context
    Hormone or placebo was given as a single daily injection.
    Summary · context
    A total of 19 women were assigned to receive rhGH at an initial daily dose of 0.043 mg/kg BW.
    Summary · context
    A total of 13 women assigned to rhGH and 14 women assigned to placebo completed 6 months of drug treatment.
    Summary · context
    In the rhGH group, 6 women took estrogen; thus, the effects of rhGH were assessed separately by estrogen status.
  16. 16HumanNon-randomized trialEfficacy outcome

    In healthy elderly women without estrogen, rhGH increased IGF-I, reaching 308 +/- 21.3 at 6 months.

    In plain wordsIn healthy elderly women without estrogen, IGF-I increased during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseIGF-I without estrogen
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Initially 0.043 mg/kg daily, with 50% reductions for side-effects; the last 7 subjects began at the reduced dose · injection · 6 monthsAs given in this study (human).

    Measurements

    IGF-I at 6 months
    308 micrograms/L
    rhGH, minus estrogen women
    IGF-I at 6 months, plus-minus spread (SD or SEM not stated)
    21.3 micrograms/L
    rhGH, minus estrogen women

    Source sentences

    Summary
    rhGH increased IGF-I and IGF-I-binding protein-3 (IGFBP-3) in all subjects [6 month IGF-I in plus estrogen women, 230 +/- 25.4 micrograms/L; in those not receiving estrogen (minus estrogen), 308 +/- 21.3].
    5 context sentences
    Summary · context
    We conducted a controlled trial of recombinant human GH (rhGH) in 27 healthy elderly women (66.7 +/- 3.0 yr), of whom 8 took a stable dose of replacement estrogen throughout the study (plus estrogen group).
    Summary · context
    Hormone or placebo was given as a single daily injection.
    Summary · context
    A total of 19 women were assigned to receive rhGH at an initial daily dose of 0.043 mg/kg BW.
    Summary · context
    A total of 13 women assigned to rhGH and 14 women assigned to placebo completed 6 months of drug treatment.
    Summary · context
    In the rhGH group, 6 women took estrogen; thus, the effects of rhGH were assessed separately by estrogen status.
  17. 17HumanNon-randomized trialEfficacy outcome

    In healthy elderly women without estrogen, hydroxyproline excretion increased by 80% during rhGH treatment.

    In plain wordsIn healthy elderly women without estrogen, hydroxyproline excretion increased by 80% during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHydroxyproline excretion without estrogen
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Initially 0.043 mg/kg daily, with 50% reductions for side-effects; the last 7 subjects began at the reduced dose · injection · 6 monthsAs given in this study (human).

    Measurements

    Hydroxyproline excretion increase
    80%
    rhGH, minus estrogen subgroup

    Source sentences

    Summary
    Hydroxyproline excretion increased by 20% and 80%, and pyridinoline excretion increased by 44% and 75% in plus and minus estrogen subgroups, respectively.
    5 context sentences
    Summary · context
    We conducted a controlled trial of recombinant human GH (rhGH) in 27 healthy elderly women (66.7 +/- 3.0 yr), of whom 8 took a stable dose of replacement estrogen throughout the study (plus estrogen group).
    Summary · context
    Hormone or placebo was given as a single daily injection.
    Summary · context
    A total of 19 women were assigned to receive rhGH at an initial daily dose of 0.043 mg/kg BW.
    Summary · context
    A total of 13 women assigned to rhGH and 14 women assigned to placebo completed 6 months of drug treatment.
    Summary · context
    In the rhGH group, 6 women took estrogen; thus, the effects of rhGH were assessed separately by estrogen status.
  18. 18HumanNon-randomized trialEfficacy outcome

    In healthy elderly women without estrogen, pyridinoline excretion increased by 75% during rhGH treatment.

    In plain wordsIn healthy elderly women without estrogen, pyridinoline excretion increased by 75% during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreasePyridinoline excretion without estrogen
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Initially 0.043 mg/kg daily, with 50% reductions for side-effects; the last 7 subjects began at the reduced dose · injection · 6 monthsAs given in this study (human).

    Measurements

    Pyridinoline excretion increase
    75%
    rhGH, minus estrogen subgroup

    Source sentences

    Summary
    Hydroxyproline excretion increased by 20% and 80%, and pyridinoline excretion increased by 44% and 75% in plus and minus estrogen subgroups, respectively.
    5 context sentences
    Summary · context
    We conducted a controlled trial of recombinant human GH (rhGH) in 27 healthy elderly women (66.7 +/- 3.0 yr), of whom 8 took a stable dose of replacement estrogen throughout the study (plus estrogen group).
    Summary · context
    Hormone or placebo was given as a single daily injection.
    Summary · context
    A total of 19 women were assigned to receive rhGH at an initial daily dose of 0.043 mg/kg BW.
    Summary · context
    A total of 13 women assigned to rhGH and 14 women assigned to placebo completed 6 months of drug treatment.
    Summary · context
    In the rhGH group, 6 women took estrogen; thus, the effects of rhGH were assessed separately by estrogen status.
  19. 19HumanNon-randomized trialEfficacy outcome

    In healthy elderly women without estrogen, osteocalcin increased by more than 60% during rhGH treatment (P < 0.05).

    In plain wordsIn healthy elderly women without estrogen, osteocalcin increased by more than 60% during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseOsteocalcin without estrogen
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Initially 0.043 mg/kg daily, with 50% reductions for side-effects; the last 7 subjects began at the reduced dose · injection · 6 monthsAs given in this study (human).

    Measurements

    Osteocalcin increase
    > 60%
    rhGH, minus estrogen women (P < 0.05)

    Source sentences

    Summary
    Osteocalcin concentrations increased by more than 60% in minus estrogen women (P < 0.05), but did not change in the plus estrogen group.
    5 context sentences
    Summary · context
    We conducted a controlled trial of recombinant human GH (rhGH) in 27 healthy elderly women (66.7 +/- 3.0 yr), of whom 8 took a stable dose of replacement estrogen throughout the study (plus estrogen group).
    Summary · context
    Hormone or placebo was given as a single daily injection.
    Summary · context
    A total of 19 women were assigned to receive rhGH at an initial daily dose of 0.043 mg/kg BW.
    Summary · context
    A total of 13 women assigned to rhGH and 14 women assigned to placebo completed 6 months of drug treatment.
    Summary · context
    In the rhGH group, 6 women took estrogen; thus, the effects of rhGH were assessed separately by estrogen status.
  20. 20HumanNon-randomized trialEfficacy outcome

    In healthy elderly women without estrogen, serum T3 increased transiently at 3 months during rhGH treatment.

    In plain wordsIn healthy elderly women without estrogen, serum T3 increased temporarily during rhGH treatment at 3 months.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseSerum T3 without estrogen
    Study

    n: not reported in source

    Outcome group
    Thyroid function · Endocrine and hormones
    Studied dose
    Initially 0.043 mg/kg daily, with 50% reductions for side-effects; the last 7 subjects began at the reduced dose · injection · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    rhGH did not alter blood pressure or circulating L-T4 levels, but a transient increase in serum T3 was observed in the minus estrogen group at 3 months.
    5 context sentences
    Summary · context
    We conducted a controlled trial of recombinant human GH (rhGH) in 27 healthy elderly women (66.7 +/- 3.0 yr), of whom 8 took a stable dose of replacement estrogen throughout the study (plus estrogen group).
    Summary · context
    Hormone or placebo was given as a single daily injection.
    Summary · context
    A total of 19 women were assigned to receive rhGH at an initial daily dose of 0.043 mg/kg BW.
    Summary · context
    A total of 13 women assigned to rhGH and 14 women assigned to placebo completed 6 months of drug treatment.
    Summary · context
    In the rhGH group, 6 women took estrogen; thus, the effects of rhGH were assessed separately by estrogen status.
  21. 21HumanNon-randomized trialEfficacy outcome

    In healthy elderly women without estrogen, rhGH decreased LDL cholesterol.

    In plain wordsIn healthy elderly women without estrogen, LDL cholesterol decreased during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseLDL cholesterol without estrogen
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Initially 0.043 mg/kg daily, with 50% reductions for side-effects; the last 7 subjects began at the reduced dose · injection · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    rhGH decreased low density lipoprotein cholesterol in the minus estrogen group, but otherwise no significant changes in circulating lipoproteins or fibrinogen were observed.
    5 context sentences
    Summary · context
    We conducted a controlled trial of recombinant human GH (rhGH) in 27 healthy elderly women (66.7 +/- 3.0 yr), of whom 8 took a stable dose of replacement estrogen throughout the study (plus estrogen group).
    Summary · context
    Hormone or placebo was given as a single daily injection.
    Summary · context
    A total of 19 women were assigned to receive rhGH at an initial daily dose of 0.043 mg/kg BW.
    Summary · context
    A total of 13 women assigned to rhGH and 14 women assigned to placebo completed 6 months of drug treatment.
    Summary · context
    In the rhGH group, 6 women took estrogen; thus, the effects of rhGH were assessed separately by estrogen status.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.